Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS)

被引：14

作者：

Bushnell, CD

Newby, LK

Goldstein, LB

Lin, F

Yaffe, K

Simon, JA

机构：

[1] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA

[3] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA

[4] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA

[5] Duke Univ, Med Ctr, Ctr Clin Hlth Policy Res, Durham, NC 27710 USA

[6] VA Med Ctr, Durham, NC USA

[7] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA

[8] Univ Calif San Francisco, Dept Neurol & Psychiat, San Francisco, CA 94143 USA

[9] VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA

来源：

NEUROLOGY | 2004年 / 62卷 / 06期

关键词：

D O I：

10.1212/01.WNL.0000115171.46508.19

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors investigated the relationship between statin use and the risk of stroke in the Heart and Estrogen - Progestin Replacement Study (HERS). Despite large reductions in relative risk point estimates, statin use was not associated with differences in the risks of all fatal stroke (relative hazard [RH] 0.52, 95% CI 0.23 to 1.18, p = 0.12), fatal ischemic stroke (RH 0.51, 95% CI 0.18 to 1.45, p = 0.21), fatal hemorrhagic stroke (RH 0.18, 95% CI 0.02 to 1.46, p = 0.11), or TIA (RH 1.32, 95% CI 0.84 to 2.09, p = 0.23).

引用

页码：968 / 970

页数：3

共 10 条

[1] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[2] Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
Endres, M
Laufs, U
Huang, ZH
Nakamura, T
Huang, P
Moskowitz, MA
Liao, JK
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8880 - 8885
[3] Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS)
Herrington, DM
Vittinghoff, E
Lin, F
Fong, J
Harris, F
Hunninghake, D
Bittner, V
Schrott, HG
Blumenthal, RS
Levy, R
[J]. CIRCULATION, 2002, 105 (25) : 2962 - 2967
[4] Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
Hulley, S
Grady, D
Bush, T
Furberg, C
Herrington, D
Riggs, B
Vittinghoff, E
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07): : 605 - 613
[5] PEDERSEN TR, 1994, LANCET, V344, P1383
[6] Reduction of stroke incidence after myocardial infarction with pravastatin -: The cholesterol and recurrent events (CARE) study
Plehn, JF
Davis, BR
Sacks, FM
Rouleau, JL
Pfeffer, MA
Bernstein, V
Cuddy, TE
Moyé, LA
Piller, LB
Rutherford, J
Simpson, LM
Braunwald, E
[J]. CIRCULATION, 1999, 99 (02) : 216 - 223
[7] Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
Rossouw, JE
Anderson, GL
Prentice, RL
LaCroix, AZ
Kooperberg, C
Stefanick, ML
Jackson, RD
Beresford, SAA
Howard, BV
Johnson, KC
Kotchen, JM
Ockene, J
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 321 - 333
[8] Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Sillesen, H
[J]. CEREBROVASCULAR DISEASES, 2003, 16 (04) : 389 - 395
[9] Postmenopausal hormone therapy and risk of stroke - The Heart and Estrogen-progestin Replacement Study (HERS)
Simon, JA
Hsia, J
Cauley, JA
Richards, C
Harris, F
Fong, J
Barrett-Connor, E
Hulley, SB
[J]. CIRCULATION, 2001, 103 (05) : 638 - 642
[10] Tonkin A, 1998, NEW ENGL J MED, V339, P1349

← 1 →